RT Journal Article SR Electronic T1 Angiogenic T cells in interstitial lung diseases JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA3620 DO 10.1183/13993003.congress-2021.PA3620 VO 58 IS suppl 65 A1 Pulito-Cueto, Verónica A1 Remuzgo-Martínez, Sara A1 Genre, Fernanda A1 Atienza-Mateo, Belén A1 Mora-Cuesta, Victor M. A1 Iturbe-Fernández, David A1 Lera-Gómez, Leticia A1 Pérez-Fernández, Raquel A1 Alonso-Lecue, Pilar A1 Rodriguez-Carrio, Javier A1 Prieto-Peña, Diana A1 Portilla, Virginia A1 Blanco, Ricardo A1 Corrales, Alfonso A1 Cifrián, Jose M. A1 López-Mejías, Raquel A1 González-Gay, Miguel A. YR 2021 UL https://publications.ersnet.org//content/58/suppl_65/PA3620.abstract AB Background: Interstitial lung diseases (ILD) lead to an increase in the patient’s morbidity and mortality. According to the etiology, ILD can be divided in disorders with either an unknown or known possible cause such as an underlying connective tissue disease (CTD) [1]. A specific T cell subset termed angiogenic T cells (TAng), that promote endothelial repair and revascularization, has been involved in the pathogenesis of CTD [2]. Nevertheless, little is known about their role in ILD.Objective: To assess the potential role of TAng in ILD.Methods: Peripheral venous blood was collected from 61 patients with ILD (composed of 21 with idiopathic pulmonary fibrosis (IPF) and 40 with CTD-ILD+), 44 CTD-ILD- patients and 20 healthy controls (HC). Quantification of TAng was performed by flow cytometry. TAng were considered as triple-positive for CD3, CD31 and CXCR4.Results: Patients with ILD exhibited a significantly lower TAng frequency than CTD-ILD- patients and HC (mean ± standard deviation: 11.98 ± 4.75 versus 16.24 ± 5.03 and 11.98 ± 4.75 versus 16.50 ± 4.83, respectively, p< 0.001 in both cases). However, no statistically significant difference was observed between CTD-ILD- patients and HC.Conclusion: Our results disclose a decrease of TAng frequency related to the presence of ILD.References: [1] J Clin Med 2020;9(6):1606; [2] Ann Rheum Dis 2015 74(5):921-7. Personal funds, VP-C: PREVAL18/01 (IDIVAL); SR-M: RD16/0012/0009 (ISCIII-ERDF); LL-G: INNVAL20/06 (IDIVAL); RP-F: START PROJECT (FOREUM); RL-M: Miguel Servet type I CP16/00033 (ISCIII-ESF).FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3620.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).